Literature DB >> 8370367

Potassium channels as pharmacological targets in cardiovascular medicine.

D Escande1, P Henry.   

Abstract

Potassium channels are membrane receptor sites for various drugs in the field of cardiovascular diseases. These channel proteins are extremely diverse, not only as regards their molecular structure but also as regards their function. Heterogeneous expression of various K+ channel subtypes is an integral part of cell specialization in different tissues. K+ channels interfere with most of the physiological processes of the cardiac muscle, of the vascular smooth muscle and of the endothelial cells. K+ channel blockers are antidiabetic agents but also antiarrhythmic drugs. K+ channel openers are used in the treatment of hypertension and most recently in the treatment of coronary heart disease. In the experimental setting, K+ channel openers afford cytoprotection during ischaemia. This exciting property opens a new field in clinical research.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8370367     DOI: 10.1093/eurheartj/14.suppl_b.2

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  3 in total

Review 1.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

2.  Effect of the potassium-channel opener nicorandil as an adjunct to cardioplegia on myocardial preservation in isolated rabbit hearts.

Authors:  Y Wang; M Sunamori; T Yoshida
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 3.  Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.

Authors:  Lamiaa Ahmed Ahmed
Journal:  Indian J Pharmacol       Date:  2019-11-26       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.